The impact of gamma hydroxybutyrate (GHB) legal restrictions on patterns of use: Results from an International Survey

Drugs: Education, Prevention and Policy

Volumn 17, Issue 5, 2010, Pages 455-469

  Anderson, I B ^a   Kim Katz, S Y ^a   Dyer, J E ^a   Blanc, P D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77956168369     PISSN: 09687637     EISSN: 14653370     Source Type: Journal    
DOI: 10.3109/09687630902729594     Document Type: Article

References (43)

1. Anderson, I. B., Kim, S. Y., Dyer, J. E., Burkhardt, C. B., Iknoian, J. C., Walsh, M. J., et al. (2006). Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Annals of Emergency Medicine, 47, 177-183.
2. Anderson, I. B., Kim-Katz, S. Y., Dyer, J. E., Earnest, G. E., Lamb, J. P., & Blanc, P. D. (2008). Area-level socioeconomic status in relation to outcomes in gamma hydroxybutyrate intoxication. Clinical Toxicology, 11, 1-10.
3. Barker, J. C., Harris, S. L., & Dyer, J. E. (2007). Experiences of gamma hydroxybutyrate (GHB) ingestion: A focus group study. Journal of Psychoactive Drugs, 39, 115-129.
4. Bosman, I. J., & Lusthof, K. J. (2003). Forensic cases involving the use of GHB in The Netherlands. Forensic Science International, 133, 17-21.
5. Burke, B. A., Lewis, R. W., Latenser, B. A., Chung, J. Y., & Willoughby, C. (2008). Pseudoephedrine legislation decreases methamphetamine laboratory-related burns. Journal of Burn Care & Research, 29, 138-140.
6. Caldicott, D. G., Chow, F. Y., Burns, B. J., Felgate, P. D., & Byard, R. W. (2004). Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia. The Medical Journal of Australia, 181, 310-313.
7. CraigsList. (2008). Craigslist online community. Accessed 9 February 2008, from http:// www.craigslist.org/about/sites.html
8. Cunningham, J. K., & Liu, L. M. (2003). Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction, 98, 1229-1237.
9. DAWN. (2004). The Dawn Report: Club Drugs, 2002 Update. Drug Abuse Warning Network, Substance Abuse & Mental Health Services Administration, US Department of Health and Human Services, Rockville, MD.
10. Degenhardt, L., & Dunn, M. (2007). The epidemiology of GHB and ketamine use in an Australian household survey. International Journal of Drug Policy, 2008 Aug; 19(4), 311-316.
11. Drugs-Forum. (2008). Drugs-Forum, International Drugs Community. Accessed, 6 November 2007, from http://www.drugs-forum.com/.
12. Duncan, D. F., White, J. B., & Nicholson, T. (2003). Using Internet-based surveys to reach hidden populations: Case of nonabusive illicit drug users. American Journal of Health Behavior, 27, 208-218.
13. Dyer, J. E., Anderson, I., Kim, S., Blanc, P., & Barker, J. (2007). Designing a gamma hydroxybutyrate (GHB) structured telephone-administered survey instrument. Journal of Medical Toxicology, 3, 7-14.
14. Dyer, J. E., Roth, B., & Hyma, B. A. (2001). Gamma-hydroxybutyrate withdrawal syndrome. Annals of Emergency Medicine, 37, 147-153.
15. ElSohly, M. A., & Salamone, S. J. (1999). Prevalence of drugs used in cases of alleged sexual assault. Journal of Analytical Toxicology, 23, 141-146.
16. EMCDDA. (2008). GHB and its precursor GBL: An emerging trend case study. EMCDDA Thematic Papers. European Monitoring Centre for Drugs and Drug Addiction, Lisbon.
17. FaceBook(2007). FaceBook. Accessed January 29, 2007, from http://www.facebook.com/
18. Federal-Register. (2000). Schedules of Controlled Substances: Addition of Gamma-Hydroxybutyric Acid to Schedule I. 21 CFR Part 1301. Retrieved May 27, 2008 from Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr12my00-11] FR Doc 00-11884 65 30541-30542.
19. Gamma, A., Jerome, L., Liechti, M. E., & Sumnall, H. R. (2005). Is ecstasy perceived to be safe? A critical survey. Drug Alcohol Depend, 77, 185-193.
20. Gonzalez, A., & Nutt, D. J. (2005). Gamma hydroxy butyrate abuse and dependency. Journal of Psychopharmacology (Oxf ), 19, 195-204.
21. Halkitis, P. N., & Palamar, J. J. (2006). GHB use among gay and bisexual men. Addictive Behaviors, 31, 2135-2139.
22. Hovda, K. E., Bjornaas, M. A., Skog, K., Opdahl, A., Drottning, P., Ekeberg, O., et al. (2008). Acute poisonings treated in hospitals in Oslo: A one-year prospective study (I): Pattern of poisoning. Clinical Toxicology (Phila), 46, 35-41.
23. Johnston, L. D., O'Malley, P. M., Bachman, J. G., Schulenberg, J. E. (2006). Monitoring the Future national results on adolescent drug use: Overview of key findings 2005. NIH publication number D6-5882. Accessed February 14, 2007, from http://www.monitoringthefuture.org/ pubs/monographs/overview2005.pdf
24. Kim, S. Y., Anderson, I. B., Dyer, J. E., Barker, J. C., & Blanc, P. D. (2007). High-risk behaviors and hospitalizations among gamma hydroxybutyrate (GHB) users. The American Journal of Drug and Alcohol Abuse, 33, 429-438.
25. Knudsen, K., Greter, J., & Verdicchio, M. (2008). High mortality rates among GHB abusers in Western Sweden. Clinical Toxicology (Phila), 46, 187-192.
26. Knudsen, K., Greter, J., Verdicchio, M., & Cederquist, T. (2005). GHB, GBL and butanediol poisonings - A serious problem in Western Sweden. Lakartidningen, 102, 3294-3296, 3299.
27. Leshner AI. (2002). Ecstacy abuse and control: hearing before the Senate Subcommittee on Governmental Affairs.
28. Liechti, M. E., Kunz, I., Greminger, P., Speich, R., & Kupferschmidt, H. (2006). Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug and Alcohol Dependency, 81, 323-326.
29. McDaniel, C. H., & Miotto, K. A. (2001). Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: Five case studies. Journal of Psychoactive Drugs, 33, 143-149.
30. Miller, P. G., Johnston, J., McElwee, P. R., & Noble, R. (2007). A pilot study using the internet to study patterns of party drug use: Processes, findings and limitations. Drug and Alcohol Review, 26, 169-174.
31. MMWR. (1999). Adverse events associated with ingestion of gamma-butyrolactone - Minnesota, New Mexico, and Texas, 1998-1999. Morbidity and Mortality Weekly Report, 48, 137-140.
32. Palmer, R. B. (2004). Gamma-butyrolactone and 1,4-butanediol: Abused analogues of gammahydroxybutyrate. Toxicological Reviews, 23, 21-31.
33. Pentney, A. R. (2001). An exploration of the history and controversies surrounding MDMA and MDA. Journal of Psychoactive Drugs, 33, 213-221.
34. ProjectGHB. (2008). Project GHB. Accessed May 25, 2008, from http://www.projectghb.org/
35. Reneau, J., Nicholson, T., White, J. B., & Duncan, D. (2000). The general well-being of recreational drug users: A survey on the WWW. International Journal of Drug Policy, 11, 315-323.
36. Scholey, A. B., Parrott, A. C., Buchanan, T., Heffernan, T. M., Ling, J., & Rodgers, J. (2004). Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/ MDMA users: A WWW study. Addictive Behaviors, 29, 743-752.
37. Tarabar, A. F., & Nelson, L. S. (2004). The gamma-hydroxybutyrate withdrawal syndrome. Toxicological Reviews, 23, 45-49.
38. United States-Canada. (2008). United States-Canada Border Drug Threat Assessment 2007: Precursor Chemicals. p. 16.
39. Wikipedia-Contributors. (2008). List of social networking websites. Wikipedia, The Free Encyclopedia.
40. Wojtowicz, J. M., Yarema, M. C., & Wax, P. M. (2008). Withdrawal from gammahydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: A case report and systematic review. Canadian Journal of Emergency Medical Care, 10, 69-74.
41. Wood, D. M., Warren-Gash, C., Ashraf, T., Greene, S. L., Shather, Z., Trivedy, C., et al. (2008). Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). Monthly Journal of the Association of Physicians, 101, 23-29.
42. YouTube. (2007). YouTube. Accessed February 14, 2007, from http://www.youtube.com/ results?search-query=dxm&search=Search
43. Zvosec, D. L., Smith, S. W., McCutcheon, J. R., Spillane, J., Hall, B. J., & Peacock, E. A. (2001). Adverse events, including death, associated with the use of 1,4-butanediol. The New England Journal of Medicine, 344, 87-94.